Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antibody drug conjugate

- PMLiVE

Merck KGaA starts third phase III trial for cancer hope TH-302

Unique method of action to target cells with low oxygen levels

- PMLiVE

Roche’s Avastin gains new US colon cancer approval

Patients can continue to use drug once disease progresses

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

Daiichi Sankyo logo

Daiichi, ArQule cancer drug tivantinib flunks another trial

Fails to meet endpoint in colorectal cancer study

EISAI

Eisai’s farletuzumab fails ovarian cancer trial

Unable to improve progression-free survival

- PMLiVE

Nexavar shows promise in thyroid cancer

Potential new indication for Bayer/Onyx drug

- PMLiVE

Matt Regan named AbbVie’s general manager in UK

Was formerly general manager of Abbott in Norway

- PMLiVE

Abbott completes split as AbbVie debuts on NYSE

New company will focus on research-based pharmaceuticals

- PMLiVE

Celgene signs $500m antibody deal with Sutro

Joins list of companies with interest in antibody-drug conjugates

- PMLiVE

Fred Powell joins Celator as chief financial officer

Joins oncology specialist from OraPharma

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

Roche’s Perjeta backed in EU for breast cancer

CHMP recommends use alongside Herceptin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links